Filing Flows › Industries › Laboratory Analytical Instruments › Capital spending and supply chain
Laboratory Analytical Instruments: capital spending and supply chain
SIC 3826 · 20 companies with filed cash-flow statements
Analysis
20 companies in Laboratory Analytical Instruments (SIC 3826) spent $1.3B on capital projects over their latest twelve months, 21% of the $5.9B their operations generated; the three largest spenders — A, ILMN, WAT — account for 53%.
Capital spending is 3.3% of the industry's $38.8B of annual revenue.
By the industry's asset mix most of it goes to equipment (44%); about $207M is imported.
The largest supplier of that spending is manufacturing structures ($202M).
Its largest supplying industries, by the input-output tables: imports ($2.3B), household appliances and electrical and electronic goods ($918M), printed circuit assembly (electronic assembly) manufacturing ($819M).
Charts
Capital spending by company
| Company | Capital spending | Operating cash flow | Capex / OCF | Period |
|---|---|---|---|---|
| A Agilent Technologies | $342M | $1.6B | 21% | TTM to Q3 FY26 |
| ILMN Illumina | $173M | $1.2B | 14% | TTM to Q3 2026 |
| WAT Waters | $151M | $550M | 27% | TTM to Q2 2026 |
| AVTR Avantor | $146M | $585M | 25% | TTM to Q3 2026 |
| BIO Bio-Rad Laboratories | $139M | $468M | 30% | TTM to Q3 2026 |
| MTD Mettler Toledo International | $114M | $984M | 12% | TTM to Q3 2026 |
| BRKR Bruker | $97.1M | $342M | 28% | TTM to Q3 2026 |
| RVTY Revvity | $69.5M | $628M | 11% | TTM to Q2 2026 |
| CTKB Cytek Biosciences | $6.9M | −$6.6M | — | TTM to Q3 2026 |
| PACB Pacific Biosciences of California | $6.4M | −$137M | — | TTM to Q3 2026 |
| TXG 10x Genomics | $5.9M | $99.7M | 6% | TTM to Q3 2026 |
| EYPT EyePoint | $4.0M | −$267M | — | TTM to Q2 2026 |
| NAUT Nautilus Biotechnology | $2.7M | −$52.5M | — | TTM to Q3 2026 |
| HBIO Harvard Bioscience | $1.8M | $651K | 272% | TTM to Q2 2026 |
| MASS 908 Devices | $876K | $1.5M | 59% | TTM to Q2 2026 |
| SEER Seer | $854K | −$43.4M | — | TTM to Q2 2026 |
| QTRX Quanterix | $762K | −$80.9M | — | TTM to Q2 2026 |
| LCTC Lifeloc Technologies | $463K | −$372K | — | TTM to Q2 2026 |
| RPID Rapid Micro Biosystems | $336K | −$40.1M | — | TTM to Q2 2026 |
| PRPO Precipio | $311K | $1.1M | 28% | TTM to Q2 2026 |
Customers and suppliers named in annual reports
| Supplier | Customer | Share of supplier revenue | Evidence | Source |
|---|---|---|---|---|
| EYPT | ANIP | 40% | Stated in 10-K (sentence) | filing |
| PRPO | Medicare & Medicaid | 40% | Stated in 10-K (sentence) | filing |
| ILMN | TEM | — | Stated in 10-K (named, share not stated) | filing |
| ILMN | NTRA | — | Stated in 10-K (named, share not stated) | filing |
| ILMN | WGS | — | Stated in 10-K (named, share not stated) | filing |
| ILMN | GH | — | Stated in 10-K (named, share not stated) | filing |
| ILMN | FLGT | — | Stated in 10-K (named, share not stated) | filing |
| ILMN | GRAL | — | Stated in 10-K (named, share not stated) | filing |
| ILMN | CAI | — | Stated in 10-K (named, share not stated) | filing |
| AVTR | ESTA | — | Stated in 10-K (named, share not stated) | filing |
| BIO | IMDX | — | Stated in 10-K (named, share not stated) | filing |
The interactive money flow: switch views, follow each dollar →
Evidence grades: A filed figure · B computed from filed figures · C industry average (BEA input-output and fixed-asset tables) applied to filed figures. Estimates are not the companies’ own records. Not investment advice.